Added anti-viral improves response, halves duration of hepatitis C treatment
Thursday, April 30, 2009 - 01:07
in Health & Medicine
The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).